Cargando…

Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models

RATIONALE: CAN-2409 is a locally delivered oncolytic therapy, which results in vaccination against the injected tumor. CAN-2409 consists of a non-replicating adenovirus armed with the Herpes virus thymidine kinase, which metabolizes ganciclovir into a phosphorylated nucleotide that is incorporated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Marilin S., Zdioruk, Mykola, Nowicki, Michal O., Hoetker, Michael S., Herbert, Zachary T., Barone, Francesca, Tak, Paul P., Chiocca, E. Antonio, Tabatabai, Ghazaleh, Lawler, Sean E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203593/
https://www.ncbi.nlm.nih.gov/pubmed/37228396
http://dx.doi.org/10.3389/fmed.2023.1140352
_version_ 1785045669560451072
author Koch, Marilin S.
Zdioruk, Mykola
Nowicki, Michal O.
Hoetker, Michael S.
Herbert, Zachary T.
Barone, Francesca
Tak, Paul P.
Chiocca, E. Antonio
Tabatabai, Ghazaleh
Lawler, Sean E.
author_facet Koch, Marilin S.
Zdioruk, Mykola
Nowicki, Michal O.
Hoetker, Michael S.
Herbert, Zachary T.
Barone, Francesca
Tak, Paul P.
Chiocca, E. Antonio
Tabatabai, Ghazaleh
Lawler, Sean E.
author_sort Koch, Marilin S.
collection PubMed
description RATIONALE: CAN-2409 is a locally delivered oncolytic therapy, which results in vaccination against the injected tumor. CAN-2409 consists of a non-replicating adenovirus armed with the Herpes virus thymidine kinase, which metabolizes ganciclovir into a phosphorylated nucleotide that is incorporated into the tumor cell’s genome, thereby inflicting immunogenic cancer cell death. While CAN-2409’s immunological impact has been well characterized, its effects on the tumor cells transcriptome remains unknown. We compared the transcriptomic landscape after treatment of glioblastoma models with CAN-2409 in vitro and in vivo to assess how the interplay with the tumor microenvironment influences CAN-2409-mediated transcriptome alterations. METHODS: We performed RNA-Seq with CAN-2409 treated patient-derived glioma stem-like cells and tumors of C57/BL6 mice and compared KEGG pathway usage and differential gene expression focusing on immune cell and cytokine profiles. T-cell -killing assays were performed to assess candidate effectors. RESULTS: PCA analysis showed distinct clustering of control and CAN-2409 samples under both conditions. KEGG pathway analysis revealed significant enrichment for p53 signaling and cell cycle pathway, with similar dynamics for key regulators of both pathways in vitro and in vivo, including MYC, CCNB1, PLK1 and CDC20. Selected alterations (PLK1 and CCNB1) were validated at the protein level. Cytokine expression analysis revealed upregulation of pro-inflammatory IL12a under both conditions; immune cell gene profiling showed reduction of myeloid associated genes. T-cell-killing assays showed increased killing in the presence of IL-12. CONCLUSION: CAN-2409 significantly alters the transcriptome both in vitro and in vivo. Comparison of pathway enrichment revealed mutual and differential utilization of pathways under both conditions, suggesting a modulating influence on the cell cycle in tumor cells, and of the tumor microenvironment on the transcriptome in vivo. IL-12 synthesis likely depends on interactions with the tumor microenvironment, and it facilitates CAN-2409 cell killing. This dataset provides potential to understand resistance mechanisms and identify potential biomarkers for future studies.
format Online
Article
Text
id pubmed-10203593
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102035932023-05-24 Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models Koch, Marilin S. Zdioruk, Mykola Nowicki, Michal O. Hoetker, Michael S. Herbert, Zachary T. Barone, Francesca Tak, Paul P. Chiocca, E. Antonio Tabatabai, Ghazaleh Lawler, Sean E. Front Med (Lausanne) Medicine RATIONALE: CAN-2409 is a locally delivered oncolytic therapy, which results in vaccination against the injected tumor. CAN-2409 consists of a non-replicating adenovirus armed with the Herpes virus thymidine kinase, which metabolizes ganciclovir into a phosphorylated nucleotide that is incorporated into the tumor cell’s genome, thereby inflicting immunogenic cancer cell death. While CAN-2409’s immunological impact has been well characterized, its effects on the tumor cells transcriptome remains unknown. We compared the transcriptomic landscape after treatment of glioblastoma models with CAN-2409 in vitro and in vivo to assess how the interplay with the tumor microenvironment influences CAN-2409-mediated transcriptome alterations. METHODS: We performed RNA-Seq with CAN-2409 treated patient-derived glioma stem-like cells and tumors of C57/BL6 mice and compared KEGG pathway usage and differential gene expression focusing on immune cell and cytokine profiles. T-cell -killing assays were performed to assess candidate effectors. RESULTS: PCA analysis showed distinct clustering of control and CAN-2409 samples under both conditions. KEGG pathway analysis revealed significant enrichment for p53 signaling and cell cycle pathway, with similar dynamics for key regulators of both pathways in vitro and in vivo, including MYC, CCNB1, PLK1 and CDC20. Selected alterations (PLK1 and CCNB1) were validated at the protein level. Cytokine expression analysis revealed upregulation of pro-inflammatory IL12a under both conditions; immune cell gene profiling showed reduction of myeloid associated genes. T-cell-killing assays showed increased killing in the presence of IL-12. CONCLUSION: CAN-2409 significantly alters the transcriptome both in vitro and in vivo. Comparison of pathway enrichment revealed mutual and differential utilization of pathways under both conditions, suggesting a modulating influence on the cell cycle in tumor cells, and of the tumor microenvironment on the transcriptome in vivo. IL-12 synthesis likely depends on interactions with the tumor microenvironment, and it facilitates CAN-2409 cell killing. This dataset provides potential to understand resistance mechanisms and identify potential biomarkers for future studies. Frontiers Media S.A. 2023-05-09 /pmc/articles/PMC10203593/ /pubmed/37228396 http://dx.doi.org/10.3389/fmed.2023.1140352 Text en Copyright © 2023 Koch, Zdioruk, Nowicki, Hoetker, Herbert, Barone, Tak, Chiocca, Tabatabai and Lawler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Koch, Marilin S.
Zdioruk, Mykola
Nowicki, Michal O.
Hoetker, Michael S.
Herbert, Zachary T.
Barone, Francesca
Tak, Paul P.
Chiocca, E. Antonio
Tabatabai, Ghazaleh
Lawler, Sean E.
Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
title Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
title_full Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
title_fullStr Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
title_full_unstemmed Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
title_short Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
title_sort uncovering transcriptomic landscape alterations of can-2409 in in vitro and in vivo glioma models
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203593/
https://www.ncbi.nlm.nih.gov/pubmed/37228396
http://dx.doi.org/10.3389/fmed.2023.1140352
work_keys_str_mv AT kochmarilins uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT zdiorukmykola uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT nowickimichalo uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT hoetkermichaels uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT herbertzacharyt uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT baronefrancesca uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT takpaulp uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT chioccaeantonio uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT tabatabaighazaleh uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels
AT lawlerseane uncoveringtranscriptomiclandscapealterationsofcan2409ininvitroandinvivogliomamodels